Linagliptin as Add on to Basal Insulin in the Elderly
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT02240680
- Locations
- 🇯🇵
Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan
🇯🇵Yoshida Memorial Hospital, Hokkaido, Sapporo, Japan
🇺🇸East Coast Institute for Research LLC at NE FL Endo & Diabetes, Jacksonville, Florida, United States
Effect of Caldine® on Renal Function in Balanced Hypertension
Terminated
- Conditions
- Hypertension
- Interventions
- Drug: DiureticsDrug: antihypertensive drugsDrug: alpha blockersDrug: Angiotensin-Converting Enzyme InhibitorsDrug: beta blockers
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5417
- Registration Number
- NCT02240641
Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36573
- Registration Number
- NCT02240654
- Locations
- 🇪🇸
1160.144.1 Boehringer Ingelheim Investigational Site, Barcelona, Spain
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT02240693
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇫🇷HOP Jean Bernard, Géria, Poitiers, Poitiers, France
🇩🇪Praxis Dr. med. Volker Schumann, Berlin, Germany
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
Phase 2
Terminated
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 79
- Registration Number
- NCT02239835
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02238184
Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8135
- Registration Number
- NCT02238275
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Phase 3
Completed
- Conditions
- Secondary PreventionStroke
- Interventions
- Drug: placebo to optional ASA as comedication
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5390
- Registration Number
- NCT02239120
- Locations
- 🇩🇪
Klinikum Coburg gGmbH, Coburg, Germany
🇩🇪Klinikzentrum Mitte, Dortmund, Dortmund, Germany
🇩🇪Klinikum Hanau GmbH, Hanau, Germany
Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 660
- Registration Number
- NCT02238145
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2318
- Registration Number
- NCT02238262